Loading
A phase 1/2 trial of FOLFOX, Gemcitabine in metastatic cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04396821 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 150 participants planned, started 2020-05-28 and due to reach its primary completion in 2026-05-30. Interventions recorded: TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel. Conditions listed: Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TST001, Transcenta, Gemcitabine, Metastatic cancer (cancer that has spread).
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic cancer (cancer that has spread).
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Metastatic cancer (cancer that has spread).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/